PAP
CTMX icon

Persistent Asset Partners’s CytomX Therapeutics CTMX Stock Holding History

Persistent Asset Partners’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14K Buy
+801
New +$4.07K 0.01% 282

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Persistent Asset Partners's CTMX Position: Q4 2025 in Review

Persistent Asset Partners sold out of CytomX Therapeutics (CTMX) in Q4 2025, closing a stake of 42,645 shares — an estimated $136K sold.

Persistent Asset Partners first reported a position in CTMX in Q3 2025 and held it in 1 quarter. The position peaked at $136K in Q3 2025. 121 funds tracked by Wall St. Rank hold CTMX as of Q4 2025.

  • Persistent Asset Partners reported no remaining CytomX Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 42,645 CytomX Therapeutics shares in Q4 2025, an estimated $136K.
  • Persistent Asset Partners first reported a position in CytomX Therapeutics in Q3 2025 and held it in 1 quarter.
  • Persistent Asset Partners's CytomX Therapeutics position peaked at $136K in Q3 2025.
  • 121 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2025.

Based on Persistent Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.